WK Bossier Health Center commemorated a significant achievement on Monday: the completion of the 50th case utilizing Focal One™ technology in treating prostate cancer. This noninvasive procedure, tailored for individuals with localized prostate cancer, debuted last December at WK Bossier. Dr. Gerard Henry initiated the first case last year, and on Monday, marked the 50th procedure, alongside urologists Dr. W. Stewart Bundrick Jr. and Dr. Christopher Wilson, who also offer the Focal One™ procedure.

Focal One™ merges real-time ultrasound image guidance with magnetic resonance imaging (MRI) and 3D biopsy data. Through a probe, the physician navigates to the tumor in real time, directing high-speed ultrasound energy specifically at the targeted area and ablating solely the affected portion of the prostate without incisions.

Dr. Henry remarked, “For low volume, low grade prostate cancer, Focal One™ stands as a very secure treatment option.”

This procedure resonates with patients as it minimizes the impact of urinary incontinence and erectile dysfunction often associated with radical prostatectomy and traditional radiation.

Focal One™ represents one among several advanced services offered to prostate cancer patients at various stages of their illness. Alongside Proton therapy, Pluvicto is part of the array of cutting-edge cancer treatments at Willis-Knighton—the sole healthcare facility in Louisiana providing proton therapy.